Senegal vs United Arab Emirates: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Senegal
91.0%
in 2025
United Arab Emirates
91.0%
in 2025
Senegal rank
61st
United Arab Emirates rank
61st
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Senegal
- United Arab Emirates
How they compare
Senegal currently reports 91.0% against 91.0% in United Arab Emirates, a difference of 0.0%.
Across all 18 years both countries report, United Arab Emirates has been ahead every year.
Senegal ranks 61st and United Arab Emirates ranks 61st of 194 countries.
United Arab Emirates has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Senegal | United Arab Emirates | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 53.8% | 97.4% | 43.6% | United Arab Emirates |
| 2020s | 88.5% | 92.2% | 3.7% | United Arab Emirates |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Senegal or United Arab Emirates?
- Senegal, at 91.0% against 91.0% in United Arab Emirates as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Senegal and United Arab Emirates?
- 0.0%, with Senegal ahead.
- How many years of comparable data are there for Senegal and United Arab Emirates?
- 18 years are reported by both, from 2008 to 2025.
- How do Senegal and United Arab Emirates rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Senegal ranks 61st and United Arab Emirates ranks 61st of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.